Recent US efforts to introduce Most Favored Nation (MFN) drug pricing are creating new layers of uncertainty for transactions involving the commercialization of prescription medicines in the US. These policies – designed to align US drug prices with the lowest prices available in comparable countries – have the potential to reshape deal economics, launch strategies, and global pricing structures. This article outlines the current MFN policy landscape and explores how these developments may affect both global and regional transactions.
